![]() |
市場調查報告書
商品編碼
1466015
幹細胞治療市場:依類型、細胞來源、治療應用、最終使用者、預測(2024-2030)Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年全球幹細胞治療市場規模為4.3983億美元,2024年達4.9323億美元,2030年將達10.2744億美元,複合年成長率為12.88%。
幹細胞療法是指在醫學上利用幹細胞來取代和修復受損的組織和器官。透過刺激身體的修復機制,這種治療方法對於治療多種疾病非常重要,包括帕金森氏症、阿茲海默症、糖尿病和心臟病。幹細胞有潛力在生命的早期階段和生長過程中產生體內各種類型的細胞。慢性病的流行和政府積極的再生治療措施正在增加全世界對幹細胞治療的需求。然而,高成本、嚴格的監管以及圍繞核准流程的擔憂給主要企業帶來了重大挑戰。公司正試圖透過遵守政府施加的嚴格標準來在這一領域保持敏捷。此外,再生醫學領域的重大發展和持續的研發活動正在為主要企業未來的業務擴張做出貢獻。
主要市場統計 | |
---|---|
基準年[2023] | 4.3983億美元 |
預計年份 [2024] | 4.9323 億美元 |
預測年份 [2030] | 10.2744億美元 |
複合年成長率(%) | 12.88% |
類型:在慢性病治療中擴大使用同種異體和自體幹細胞療法
同種異體移植是一種將幹細胞從捐贈者移植到另一個接受者的治療方法。當患者的細胞不適合治療時,例如遺傳性疾病,這種治療方法通常是首選。它還具有易於獲得並允許快速治療的優點。另一方面,自體幹細胞療法使用從患者的骨髓、脂肪組織或血液中提取的幹細胞。這種類型的治療方法免疫排斥的風險較低,因為細胞取自患者體內。
細胞來源:在組織重塑和組織修復中擴大採用 AD-MSC 和 BM-MSC
脂肪組織間質幹細胞(AD-MSC)是從脂肪組織(通常稱為體脂肪)中獲得的。這些細胞引起了人們極大的興趣,因為它們相對容易獲得。 AD-MSC 的萃取比其他來源需要更少的侵入性操作,並且可以在局部麻醉下透過抽脂手術進行。 AD-MSC 可分化為多種細胞類型、分泌生長因子並調節免疫反應,因此可用於多種治療方法。同時,從骨髓(通常是骨盆的髂嵴)中間質幹細胞(BM-MSC)。 BM-MSC 是廣泛研究的幹細胞之一,已知具有分化成骨、軟骨和脂肪組織的潛力。 BM-MSC 還具有強大的免疫調節特性,使其成為治療自體免疫疾病和支持骨髓移植植入的有力候選者。另一方面,胎盤臍帶間間質幹細胞(PC-UC-MSC)是在出生後從胎盤和臍帶中獲得的。這些細胞可以非侵入性地收穫,並且與 AD-MSC 和 BM-MSC 等成體幹細胞相比具有較高的增殖率。
治療應用:再生醫學在各個治療領域日益普及
幹細胞被認為是治療各種心血管疾病(包括心肌梗塞和鬱血性心臟衰竭)的突破性選擇。基於幹細胞的手術有可能再生受損的心臟組織、改善心臟功能並刺激心臟細胞修復。在狼瘡和類風濕性關節炎等疾病中,硬化幹細胞療法可以改變疾病進程並恢復免疫平衡。這些細胞可以調節 T 細胞反應,並已用於治療某些自體免疫疾病。幹細胞療法可望再生軟骨、骨骼和肌肉組織,以治療骨關節炎、肌肉萎縮症萎縮症和其他肌肉骨骼疾病。這種治療方法旨在減輕疼痛、改善功能,並延遲或避免關節重建手術等侵入性治療的需要。幹細胞療法治療阿茲海默症神經系統疾病的潛力在於其保護、修復和取代神經細胞和神經膠質細胞的能力。幹細胞已顯示出促進傷口癒合的重要能力。透過在傷口護理中使用間質幹細胞,這些細胞可以促進皮膚組織再生、減少疤痕並縮短癒合時間。這對於燒燙傷患者、糖尿病潰瘍患者以及創傷治療緩慢的患者尤其重要。
最終用戶:學術研究中心和醫院更多地使用幹細胞療法,以提供有效、安全和標準化的治療結果
學術和研發中心對於推進幹細胞科學至關重要,需要各種幹細胞來推進疾病研究、藥物開發和突破性治療方法的開發。這些機構對開創性研究做出了重大貢獻,並且是幹細胞應用創新的溫床。另一方面,門診手術中心(ASC)為某些類型的門診幹細胞治療提供了一個場所。這些中心比醫院需要更少的資源,使它們成為患者和付款人的具有成本效益的選擇。醫院和診所仍然是幹細胞治療的主要場所,特別是對於複雜和急性疾病。醫院和診所服務的患者的多樣性推動了對各種幹細胞治療的需求,包括針對白血病和淋巴瘤等疾病的造血幹細胞移植(HSCT)以及各種再生醫學應用。生物製藥公司在幹細胞療法的開發和商業化中發揮著重要作用。他們購買幹細胞不僅用於研究和開發目的,例如發現新藥和開發再生醫學,而且還用於製造目的,利用幹細胞株大規模生產治療產品。生物製藥公司對幹細胞療法的興趣與其不斷尋找比現有藥物提供更好治療效果的創新治療方法是一致的。生物製藥公司正在致力於幹細胞療法的開發和商業化。購買幹細胞不僅用於研究和開發目的,例如發現新藥和開發再生醫學,而且還用於製造目的,其中幹細胞株用於大規模生產治療產品。
區域洞察
美國和加拿大等國家擁有發達的醫療保健基礎設施和較高的慢性病發病率,增加了對幹細胞療法等創新治療方法的需求。客戶的購買行為反映了採用新醫療保健技術的強烈趨勢,特別是在再生醫學等領域。該地區在幹細胞專利方面的領先地位支持了強大且不斷發展的治療市場,大量的研究投資和活動證明了這一點。歐盟(EU)為幹細胞治療提供了多元化的空間,德國、英國和法國等國家則專注於研究和臨床應用。同時,由於在改善醫療保健方面的大量投資以及對先進醫學的需求不斷增加,中東和非洲對幹細胞療法的興趣正在迅速增加。杜拜細胞治療和再生醫學框架等舉措旨在將該地區定位為幹細胞治療醫療旅遊中心。同時,在亞洲,中國、日本和印度等國家的幹細胞治療市場迅速擴大,政府的支持性政策為研究和創新創造了蓬勃發展的環境。日本和中國擁有快速核准再生醫學產品的先進法規,使這些國家成為採用幹細胞療法的主要空間。在印度,醫療保健基礎設施正在改善,公共和私人研究經費正在增加,幹細胞治療的使用正在擴大,並且正在轉向研究和開發。
FPNV定位矩陣
FPNV定位矩陣對於評估幹細胞治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對幹細胞治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.幹細胞治療市場的市場規模與預測是多少?
2.幹細胞治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3. 幹細胞治療市場的技術趨勢和法規結構是什麼?
4.幹細胞治療市場主要廠商的市場佔有率是多少?
5. 進入幹細胞治療市場的合適形式和策略性手段是什麼?
[195 Pages Report] The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.
Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 439.83 million |
Estimated Year [2024] | USD 493.23 million |
Forecast Year [2030] | USD 1,027.44 million |
CAGR (%) | 12.88% |
Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
Allogeneic stem cell therapy involves the transplantation of stem cells from a donor to another recipient. This therapy is often preferred in conditions for patients with cells unsuitable for therapy, such as in cases with genetic disorders. It also allows for off-the-shelf solutions, leading to rapidness in treatment administration. On the other hand, autologous stem cell therapy uses a patient's stem cells collected from their bone marrow, adipose tissue, and blood. This type of therapy is associated with a lower risk of immune rejection since the cells are derived from the patient's body.
Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are obtained from adipose tissue, commonly known as body fat. These cells are of significant interest due to their relative ease of access. The extraction of AD-MSCs involves less invasive procedures than other sources and can be done under local anesthesia via liposuction. AD-MSCs are used in various therapeutic approaches because they differentiate into multiple cell types, secrete growth factors, and modulate immune responses. At the same time, bone marrow-derived mesenchymal stem cells (BM-MSCs) are harvested from the bone marrow, typically from the iliac crest of the pelvis. They are among the extensively studied stem cells with known potential to differentiate into bone, cartilage, and adipose tissue. BM-MSCs also have robust immunomodulatory properties, making them prominent candidates for treating autoimmune diseases and supporting engraftment in bone marrow transplantation. While, placental and umbilical cord-derived mesenchymal stem cells (PC-UC-MSCs) are obtained from the placenta and the umbilical cord following childbirth. These cells are non-invasive to collect and have a higher proliferation rate than adult stem cells, such as AD-MSCs and BM-MSCs.
Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
Stem cells are being explored as a revolutionary option in the treatment of various cardiovascular diseases, including myocardial infarction and congestive heart failure. Procedures utilizing stem cells have the potential to regenerate damaged heart tissue, improve heart function, and stimulate the repair of cardiac cells. In diseases including lupus and rheumatoid arthritis, sclerosis stem cell therapy can modify the disease process and restore immune balance. These cells can modulate T-cell responses and have been used to treat certain autoimmune diseases. For conditions such as osteoarthritis, muscular dystrophy, and other musculoskeletal disorders, stem cell therapy is promising for regenerating cartilage, bone, and muscle tissues. The treatment aims to reduce pain, improve function, and possibly delay or avoid the need for more invasive treatments like joint replacements. Stem cell therapy's potential to treat neurological disorders such as Alzheimer's is its capacity to protect, repair, or replace neurons and glial cells. Stem cells demonstrate a significant capacity to enhance the healing of wounds and injuries. By deploying MSCs in wound care, these cells can promote the regeneration of skin tissue, reduce scarring, and improve healing times. This is particularly relevant for burn victims, patients with diabetic ulcers, or individuals who experience slow wound healing.
End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
Academic & research centers are crucial in advancing stem cell science and require various stem cell types to propel disease study, medication development, and therapy innovation breakthroughs. These institutions significantly contribute to pioneering studies and serve as a breeding ground for innovation in stem cell applications. On the other hand, ambulatory surgical centers (ASCs) provide a setting for certain types of outpatient stem cell therapies. These centers, less resource-intensive than hospitals, offer a cost-effective alternative for patients and insurers. Hospitals and clinics remain the primary care setting for the administration of stem cell therapies, particularly for more complex and acute medical conditions. The diverse patient population they serve creates a need for a broad range of stem cell therapies, including hematopoietic stem cell transplantation (HSCT) for diseases such as leukemia and lymphoma and various regenerative medicine applications. Biopharmaceutical companies are key players in the development and commercialization of stem cell therapies. They not only purchase stem cells for R&D purposes - working on new drug discoveries and development of regenerative medicine - but also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale. Biopharma's interest in stem cell therapies corresponds with its ongoing search for innovative treatments that offer improved outcomes over existing medicines. Biopharmaceutical companies work on the development and commercialization of stem cell therapies. They purchase stem cells for R&D purposes to on new drug discoveries and the development of regenerative medicine and also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale.
Regional Insights
In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Stem Cell Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?
3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?
4. What is the market share of the leading vendors in the Stem Cell Therapy Market?
5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?